---
schema_version: "secwatch.filing_event.v1"
accession: "0001564590-22-022527"
form_type: "8-K/A"
ticker: "TXMD"
cik: "0000025743"
company_name: "TherapeuticsMD, Inc."
filed_at: "2022-06-06T23:59:59+00:00"
generated_at: "2026-06-25T04:29:53.435731+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# TherapeuticsMD adopts bylaw amendment facilitating acquisition by Athene Parent via tender offer and merger

## Summary
- Bylaw amendment adopted May 27, 2022, makes Nevada control share statutes inapplicable to the merger agreement with Athene Parent and Merger Sub.
- Amendment enables cash tender offer for all outstanding TXMD common stock and subsequent merger.
- This 8-K/A corrects item number from 1.01 to 5.03; no disclosure changes from the original June 3, 2022 filing.

## SEC filing metadata
- accession: 0001564590-22-022527
- form_type: 8-K/A
- ticker: TXMD
- cik: 0000025743
- company_name: TherapeuticsMD, Inc.
- filed_at: 2022-06-06T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 5.03, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/25743/000156459022022527/0001564590-22-022527-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/25743/000156459022022527/txmd-8ka_20220527.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001564590-22-022527
- JSON: https://secwatch.observer/filing/0001564590-22-022527.json
- Plain text: https://secwatch.observer/filing/0001564590-22-022527.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.